VA awards $33.6M for Bremelanotide autoinjectors to Cosette Pharmaceuticals under full and open competition
Contract Overview
Contract Amount: $33,647 ($33.6K)
Contractor: Cosette Pharmaceuticals, Inc.
Awarding Agency: Department of Veterans Affairs
Start Date: 2025-12-20
End Date: 2026-12-19
Contract Duration: 364 days
Daily Burn Rate: $92/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 1
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: BREMELANOTIDE (VYLEESI) 1.75MG/0.3ML AUTOINJECTOR.
Place of Performance
Location: SOUTH PLAINFIELD, MIDDLESEX County, NEW JERSEY, 07080
Plain-Language Summary
Department of Veterans Affairs obligated $33,647 to COSETTE PHARMACEUTICALS, INC. for work described as: BREMELANOTIDE (VYLEESI) 1.75MG/0.3ML AUTOINJECTOR. Key points: 1. The VA is procuring Bremelanotide (Vyleesi) autoinjectors, a medication for hypoactive sexual desire disorder in premenopausal women. 2. Cosette Pharmaceuticals, Inc. is the awardee, indicating a competitive market for this pharmaceutical product. 3. The contract is a Firm Fixed Price Delivery Order, suggesting predictable costs for the VA. 4. The award period runs through December 2026, ensuring supply continuity.
Value Assessment
Rating: good
The contract value of $33.6M for a 1-year period (with potential for extension) appears reasonable given the specialized nature of the pharmaceutical product. Benchmarking against similar specialized drug procurements would provide further clarity.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, which typically drives competitive pricing. The use of a Delivery Order under an existing contract structure suggests a streamlined procurement process.
Taxpayer Impact: The competitive award process is expected to yield fair pricing, maximizing the value of taxpayer dollars spent on this medication.
Public Impact
Ensures access to a specific medication for eligible veterans. Supports the pharmaceutical manufacturing sector. Provides a consistent supply of a critical drug for patient treatment.
Waste & Efficiency Indicators
Waste Risk Score: 92 / 10
Positive Signals
- Full and open competition
- Firm Fixed Price contract type
- Clear awardee and product specified
Sector Analysis
This award falls within the Pharmaceutical Preparation Manufacturing sector. Spending in this sector is driven by healthcare needs and the development of new and existing treatments. The VA's procurement aligns with general government healthcare spending trends.
Small Business Impact
The awardee, Cosette Pharmaceuticals, Inc., is not identified as a small business. The contract does not appear to have specific small business set-aside provisions.
Oversight & Accountability
The Department of Veterans Affairs is responsible for overseeing this contract. Standard contract management practices should ensure delivery and quality standards are met.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Veterans Affairs Contracting
- Department of Veterans Affairs Programs
Risk Flags
- Potential for price increases in future contract periods.
- Dependence on a single supplier for this specific medication.
- Limited public information on the specific clinical utility and demand within the VA.
Tags
pharmaceutical-preparation-manufacturing, department-of-veterans-affairs, nj, delivery-order, under-100k
Frequently Asked Questions
What is this federal contract paying for?
Department of Veterans Affairs awarded $33,647 to COSETTE PHARMACEUTICALS, INC.. BREMELANOTIDE (VYLEESI) 1.75MG/0.3ML AUTOINJECTOR.
Who is the contractor on this award?
The obligated recipient is COSETTE PHARMACEUTICALS, INC..
Which agency awarded this contract?
Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).
What is the total obligated amount?
The obligated amount is $33,647.
What is the period of performance?
Start: 2025-12-20. End: 2026-12-19.
What is the historical pricing trend for Bremelanotide (Vyleesi) and how does this award compare?
Analyzing historical pricing data for Bremelanotide (Vyleesi) is crucial to assess the value of this $33.6M award. If previous contracts or market prices were significantly lower, this award might warrant further scrutiny. Conversely, if prices have remained stable or increased due to market factors, the current award could represent a fair market price achieved through competitive bidding.
What are the specific clinical indications and patient population served by Bremelanotide (Vyleesi) within the VA system?
Understanding the clinical indications for Bremelanotide (Vyleesi), primarily hypoactive sexual desire disorder in premenopausal women, helps contextualize its necessity within the VA healthcare system. Identifying the target patient population and estimated demand is essential for evaluating the appropriateness of the $33.6M expenditure and ensuring it aligns with veteran healthcare needs and priorities.
Are there any alternative treatments for hypoactive sexual desire disorder being considered or procured by the VA?
Investigating alternative treatments for hypoactive sexual desire disorder within the VA's procurement strategy is important for assessing cost-effectiveness and patient care options. If other, potentially more cost-effective or clinically superior, alternatives exist or are being developed, the long-term value and necessity of this specific Bremelanotide contract could be questioned.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY
Offers Received: 1
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 111 COOLIDGE ST, SOUTH PLAINFIELD, NJ, 07080
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Self-Certified Small Disadvantaged Business, Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $33,647
Exercised Options: $33,647
Current Obligation: $33,647
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Parent Contract
Parent Award PIID: 36F79720D0191
IDV Type: FSS
Timeline
Start Date: 2025-12-20
Current End Date: 2026-12-19
Potential End Date: 2026-12-19 00:00:00
Last Modified: 2026-04-02
Other Department of Veterans Affairs Contracts
- CCN Region 3 Express Report — $5.2B (Optum Public Sector Solutions, Inc.)
- Express Report for FY22 Region 2 — $5.1B (Optum Public Sector Solutions, Inc.)
- Fiscal Year 2022 Express Report for Region 1 — $4.2B (Optum Public Sector Solutions, Inc.)
- Express Report for the Patient Centered Community Care (PC3) Contract — $3.3B (Triwest Healthcare Alliance Corp)
- CCN Region Three FY21 Express Report — $3.1B (Optum Public Sector Solutions, Inc.)